Efficacy of Longdan Xiegan Decoction on the Treatment of Eczema: A Systematic Review and Meta-Analysis

Table 1

The general characteristics of the 14 trials.

Study	Sample size (T/C)	Course of the disease (mean or range) (T/C)	Age (mean or range) (T/C)	Intervention		Duration of use	Outcome
				T	C
Jin Deng, 2017 [12]	65/60	NR	44.2 ± 5.3/42.8 ± 4.6	LDXGD + ebastine	Ebastine	10d	1, 2, 4
Xiangbo Dong, 2013 [13]	36/36	NR	NR	LDXGD + ebastine	Ebastine	14d	1, 2
Hui Hui, 2016 [18]	50/50	NR	NR	LDXGD + compound econazole nitrate cream	Compound econazole nitrate cream	15d	1, 2, 3
Dashan Qian, 2019 [19]	26/26	(3.25 ± 1.13/4.23 ± 1.11) m	35.31 ± 10.24/36.25 ± 10.16	LDXGD + azelastine	Azelastine	10d	1, 2, 4, 5, 6, 7
Dahua Wu, 2019 [14]	39/39	NR	NR	LDXGD + cetirizine	Cetirizine	21d	1, 2, 4, 5, 6, 7
Zhulan Zhou, 2010 [15]	44/41	NR	38.95 ± 15.36/39.31 ± 15.71	LDXGD + qumixin cream	Qumixin cream	21d	1, 2, 3
Xianggong Zhu, 2016 [20]	40/40	(5.5 ± 2.3/5.3 ± 2.1) m	44.1 ± 4.8/43.5 ± 4.7	LDXGD + cetirizine	Cetirizine	10d	1, 2, 4, 5, 6, 7
Zushu Duan, 2011 [16]	30/30	(5.15 ± 3.76/6.74 ± 4.47) d	37.54 ± 9.36/35.13 ± 12.91	LDXGD	Cetirizine	14d	1, 2
Qifang Gao, 2016 [21]	25/25	(9.03 ± 0.96/8.64 ± 0.81) d	41.09 ± 8.03/40.63 ± 7.65	LDXGD	Loratadine	NR	1, 2
Jianming Li, 2019 [22]	25/25	(2.1 ± 0.60/2.10 ± 0.57) y	36.6 ± 2.17/36.78 ± 2.25	LDXGD	Cetirizine	21d	1, 2, 3
Chengcheng Liao, 2017 [23]	34/34	(1.53 ± 0.53/1.32 ± 0.64) d	34.67 ± 12.75/35.21 ± 13.25	LDXGD	Loratadine	14d	1, 2
Yanshun Lu, 2011 [24]	42/41	(5.39 ± 1.22/5.27 ± 2.13) d	36.25 ± 4.38/35.94 ± 6.03	LDXGD	Levocetirizine	21d	1, 2
Jihong Luo, 2013 [25]	40/40	(2.6 ± 1.1/2.8 ± 1.3) y	64.2 ± 5.4/65.3 ± 4.8	LDXGD	Cetirizine	21d	1, 2
Wenwei Ye, 2009 [26]	52/45	112/113 d	36.6/36.9	LDXGD	Ebastine	20d	1, 2, 4

T: experimental group; C: control group; NR: no record; d: day; m: month; y: year; 1: cure rate; 2: total effective rate; 3: recurrence rate; 4: adverse reaction rate; 5: IL-6; 6: IL-8; and 7: TNF-α.